Published in Healthcare Finance, Tax and Law Weekly, June 30th, 2004
According to recent research from the United States, "[i]nfliximab (Remicade), a chimeric monoclonal antibody to tumor necrosis factor-alpha (anti-TNF-alpha), is being used with increasing frequency in the treatment of Crohn disease."
"Infliximab's safety profile to date has been good with reported adverse events being mild to moderate," noted S. Panagi and coauthors at Lenox Hill Hospital in New York City. However, the collaborators described "a case of diffuse alveolar hemorrhage after the second infliximab infusion in a patient with Crohn disease."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.